AIMS: To evaluate the effectiveness and safety of bivalirudin as used in routine care. Bivalirudin has been studied as an alternative to heparin plus glycoprotein IIb/IIIa inhibitor (GPI) during percutaneous coronary intervention (PCI). Trials have indicated that bivalirudin is non-inferior to heparin with respect to death and repeat revascularization and may decrease the risk of major bleeds. The use of bivalirudin in routine care has not been evaluated. METHODS AND RESULTS: Using a representative database, we identified 127 185 individuals who underwent inpatient PCI between June 2003 and December 2006 and were administered either bivalirudin plus provisional GPI or the comparator, heparin plus GPI. We estimated relative risks of blood transfusion, repeated PCI, and in-hospital death. The adjusted hazard ratio (HR) for blood transfusion was 0.67 (0.61-0.73); instrumental variable analysis showed an HR of 0.72 (0.12-4.47). We observed a risk of in-hospital death of 0.80% in the bivalirudin group and 2.1% in the heparin group; the adjusted HR was 0.51 (0.44-0.60). CONCLUSION: In our non-randomized study of routine care, we observed a reduction in blood transfusions and in short-term mortality for patients treated with bivalirudin compared with heparin plus GPI. The mortality benefit was more pronounced in our study than in randomized trials.
AIMS: To evaluate the effectiveness and safety of bivalirudin as used in routine care. Bivalirudin has been studied as an alternative to heparin plus glycoprotein IIb/IIIa inhibitor (GPI) during percutaneous coronary intervention (PCI). Trials have indicated that bivalirudin is non-inferior to heparin with respect to death and repeat revascularization and may decrease the risk of major bleeds. The use of bivalirudin in routine care has not been evaluated. METHODS AND RESULTS: Using a representative database, we identified 127 185 individuals who underwent inpatient PCI between June 2003 and December 2006 and were administered either bivalirudin plus provisional GPI or the comparator, heparin plus GPI. We estimated relative risks of blood transfusion, repeated PCI, and in-hospital death. The adjusted hazard ratio (HR) for blood transfusion was 0.67 (0.61-0.73); instrumental variable analysis showed an HR of 0.72 (0.12-4.47). We observed a risk of in-hospital death of 0.80% in the bivalirudin group and 2.1% in the heparin group; the adjusted HR was 0.51 (0.44-0.60). CONCLUSION: In our non-randomized study of routine care, we observed a reduction in blood transfusions and in short-term mortality for patients treated with bivalirudin compared with heparin plus GPI. The mortality benefit was more pronounced in our study than in randomized trials.
Authors: Mandeep Singh; Ryan J Lennon; David R Holmes; Malcolm R Bell; Charanjit S Rihal Journal: J Am Coll Cardiol Date: 2002-08-07 Impact factor: 24.094
Authors: Jeffrey J Popma; Peter Berger; E Magnus Ohman; Robert A Harrington; Cindy Grines; Jeffrey I Weitz Journal: Chest Date: 2004-09 Impact factor: 9.410
Authors: T A Brennan; L E Hebert; N M Laird; A Lawthers; K E Thorpe; L L Leape; A R Localio; S R Lipsitz; J P Newhouse; P C Weiler Journal: JAMA Date: 1991-06-26 Impact factor: 56.272
Authors: A Michael Lincoff; John A Bittl; Robert A Harrington; Frederick Feit; Neal S Kleiman; J Daniel Jackman; Ian J Sarembock; David J Cohen; Douglas Spriggs; Ramin Ebrahimi; Gadi Keren; Jeffrey Carr; Eric A Cohen; Amadeo Betriu; Walter Desmet; Dean J Kereiakes; Wolfgang Rutsch; Robert G Wilcox; Pim J de Feyter; Alec Vahanian; Eric J Topol Journal: JAMA Date: 2003-02-19 Impact factor: 56.272
Authors: A Michael Lincoff; Neal S Kleiman; Dean J Kereiakes; Frederick Feit; John A Bittl; J Daniel Jackman; Ian J Sarembock; David J Cohen; Douglas Spriggs; Ramin Ebrahimi; Gadi Keren; Jeffrey Carr; Eric A Cohen; Amadeo Betriu; Walter Desmet; Wolfgang Rutsch; Robert G Wilcox; Pim J de Feyter; Alec Vahanian; Eric J Topol Journal: JAMA Date: 2004-08-11 Impact factor: 56.272
Authors: Joshua J Gagne; Jennifer M Polinski; Jeremy A Rassen; Michael A Fischer; John D Seeger; Jessica M Franklin; Jun Liu; Sebastian Schneeweiss; Niteesh K Choudhry Journal: Drug Saf Date: 2015-11 Impact factor: 5.606
Authors: Navin K Kapur; Chetan Shenoy; Adil A Yunis; Najwa N Mohammad; Szuhuei Wilson; Vikram Paruchuri; Emily E Mackey; Xiaoying Qiao; Ameer Shah; Michele L Esposito; Richard H Karas; Iris Z Jaffe Journal: PLoS One Date: 2012-04-11 Impact factor: 3.240
Authors: Suzanne V Arnold; Shu-Xia Li; Karen P Alexander; John A Spertus; Brahmajee K Nallamothu; Jeptha P Curtis; Mikhail Kosiborod; Aakriti Gupta; Tracy Y Wang; Haiqun Lin; Kumar Dharmarajan; Kelly M Strait; Timothy J Lowe; Harlan M Krumholz Journal: J Am Heart Assoc Date: 2015-06-15 Impact factor: 5.501